SCHEMBL10088515

SCHEMBL10088515

Cc1sc(CO)cc1-c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.44
ALDH1A1 P00352 3/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PTGS2 P35354 1/20 0.37
MAPT P10636 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
AHR P35869 1/20 0.36
APEX1 P27695 1/20 0.35
PRKCZ Q05513 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
IKBKB O14920 1/20 0.35
LIMK1 P53667 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876512 0.76 ALOX15 (0.39) ALDH1A1SMN1; SMN2CA12CA9LIMK1
SCHEMBL10088967 0.75 S1PR1 (0.42) NOTUMGAAPTGS2
SCHEMBL10493450 0.74 IKBKB (0.43) NOTUMALDH1A1LMNAGAASMN1; SMN2
SCHEMBL2850192 0.73 ESR1 (0.41) NOTUMALDH1A1GAASMN1; SMN2PTGS2
SCHEMBL19029875 0.69 CYP2A6 (0.32)
SCHEMBL6018650 0.68 ALDH1A1 (0.38) ALDH1A1LMNAGAASMN1; SMN2MAPT
SCHEMBL1160546 0.68 ALDH1A1 (0.52) NOTUMALDH1A1GAAMAPTCYP2C9
SCHEMBL11246897 0.68
SCHEMBL16049281 0.67 NOTUM (0.46) NOTUMALDH1A1LMNAGAASMN1; SMN2
SCHEMBL14012059 0.67 CYP2A6 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 NOTUM 1923/4885ALDH1A1 2201/4885LMNA 1651/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 NOTUM 2819/4885ALDH1A1 2294/4885LMNA 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.